Featured Research

from universities, journals, and other organizations

How protein blocks HIV life cycle in elite controllers

Date:
June 11, 2014
Source:
Massachusetts General Hospital
Summary:
A research team has learned more about one way the immune systems of elite controllers – those rare individuals able to control HIV infection without drug treatment – block a key step in the virus's life cycle. They report finding that p21, a protein best known as a tumor suppressor, inhibits reverse transcription by blocking a human enzyme essential to the process.

Investigators from Massachusetts General Hospital (MGH) and the Ragon Institute of MGH, MIT and Harvard have learned more about one way the immune systems of elite controllers -- those rare individuals able to control HIV infection without drug treatment -- block a key step in the virus's life cycle. In a paper appearing in Cell Host & Microbe, the research team reports finding the mechanism behind the ability of p21, a protein best known as a tumor suppressor, to inhibit reverse transcription, the process of converting viral RNA into DNA.

"Many of the drugs currently being used to treat HIV infection target this essential viral replication step, but it's been uncertain whether reverse transcription can be naturally inhibited in a clinically significant way," says Mathias Lichterfeld, MD, of the MGH Infectious Disease Division, the paper's corresponding author. "Our studies show that a human enzyme is required for HIV reverse transcription and that the upregulation of p21 -- an intrinsic inhibitor of similar enzymes -- can block viral reverse transcription."

Fewer than 1 percent of individuals infected with HIV can naturally suppress viral replication without antiviral treatment, an ability that keeps viral levels low -- sometimes to a level where they cannot be detected with standard assays -- and prevents the HIV-induced breakdown of the immune system. Since 2006 researchers at the Ragon Institute have been leading the International HIV Controllers study to investigate factors underlying this rare ability, a project that has enrolled more than 1,500 controllers worldwide and has identified a number of immune factors that interfere with viral growth within CD4 T cells, the virus's primary targets.

In 2011, Lichterfeld led a team that found the expression of p21 was significantly elevated in CD4 cells of HIV controllers and that experimentally knocking out the protein's expression could increase viral replication in controllers' cells. That study showed that p21 expression interfered with both reverse transcription, which produces the viral DNA that will be integrated into the genome of infected CD4 cells, and with the production of new RNA molecules to be used to create new viral particles. The current study was designed to investigate the molecular mechanism by which p21 inhibits reverse transcription.

Since p21 is known to inhibit a family of enzymes called cyclin-dependent kinases (CDKs), the research team examined whether p21 inhibits reverse transcription by blocking a CDK enzyme. In a series of experiments they found that the activity of an enzyme called CDK2 is required to protect reverse transcriptase from breakdown by cellular enzymes, identified the site of CDK2's activity on the reverse transcriptase molecule, and showed that p21 inhibits reverse transcription of viral RNA by blocking the protective activity of CDK2.

"An important point is that p21 inhibits reverse transcription by an indirect mechanism that blocks a required human cellular enzyme but not by direct interaction with the virus itself," explains Lichterfeld, an assistant professor of Medicine at Harvard Medical School. "Pharmaceutical inhibitors of reverse transcription act by binding to the reverse transcriptase molecule, a process that the virus can circumvent by sequence mutations. Moreover, this study gives a great example of how much HIV depends on human proteins to replicate and how this dependence exposes the virus to specific inhibitory effects of the immune system. We hope that identifying this new viral vulnerability that is naturally exploited in HIV controllers may help us design new strategies that can someday lead to a drug-free remission of HIV infection in many more infected individuals."


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jin Leng, Hsin-Pin Ho, MariaJ. Buzon, Florencia Pereyra, BruceD. Walker, XuG. Yu, EmmanuelJ. Chang, Mathias Lichterfeld. A Cell-Intrinsic Inhibitor of HIV-1 Reverse Transcription in CD4 T Cells from Elite Controllers. Cell Host & Microbe, 2014; 15 (6): 717 DOI: 10.1016/j.chom.2014.05.011

Cite This Page:

Massachusetts General Hospital. "How protein blocks HIV life cycle in elite controllers." ScienceDaily. ScienceDaily, 11 June 2014. <www.sciencedaily.com/releases/2014/06/140611132032.htm>.
Massachusetts General Hospital. (2014, June 11). How protein blocks HIV life cycle in elite controllers. ScienceDaily. Retrieved July 26, 2014 from www.sciencedaily.com/releases/2014/06/140611132032.htm
Massachusetts General Hospital. "How protein blocks HIV life cycle in elite controllers." ScienceDaily. www.sciencedaily.com/releases/2014/06/140611132032.htm (accessed July 26, 2014).

Share This




More Health & Medicine News

Saturday, July 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins